ESMO 2026 | MIZAR-003: extended follow-up of GC101 TIL therapy in advanced melanoma
Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands, discusses extended follow-up results from the Phase II MIZAR-003 trial (NCT06703398), which compared GC101, an autologous tumor-infiltrating lymphocyte (TIL) therapy, with investigator-choice chemotherapy in anti-PD-1-refractory advanced melanoma. GC101 significantly improved progression-free survival and response rates, with benefit seen across mucosal and acral subtypes. A favorable but immature overall survival trend was observed, warranting further follow-up for definitive confirmation. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
